GERN News and Press, Geron Corporation From 03/12/24

2024-03-12 11:00:48 ET More on Geron Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA Geron Corporation (GERN) Q4 2023 Earnings Call Transcript Geron's Ideal Situation Appears To Be Already Priced In Seeking Alpha’s Quant Rati...

2024-03-10 13:08:00 ET More on ALX Oncology, Bicycle Therapeutics, etc. Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. 2023 Q4 - Results - Earnings Call Presentation ...

2024-03-05 10:30:29 ET Summary Geron Corporation's lead candidate, imetelstat, is awaiting FDA approval for the treatment of transfusion-dependent anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes. The company reported a loss from operations of $19...

2024-02-28 11:45:15 ET Image source: The Motley Fool. Geron (NASDAQ: GERN) Q4 2023 Earnings Call Feb 28, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Geron (GERN) Q4 2023 Earnings Call Transcript

SilverBow Resorces Inc. (SBOW) is expected to report $2.36 for Q4 2023 FAT Brands Inc. Class B Common Stock (FATBB) is expected to report for quarter end 2023-12-31 Ecovyst Inc. (ECVT) is expected to report $0.2 for Q4 2023 MYR Group Inc. (MYRG) is expected to report $1.41 for Q4 2023...

2024-02-25 08:00:00 ET The last week of February promises a dynamic mix of earnings reports across various sectors. In the technology space, investors are eagerly anticipating updates from Salesforce ( NYSE: CRM ), Snowflake ( NYSE: SNOW ), Zoom Video Communications ( NASD...

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its fourth quarter and full-year 2023 financial results and business highlights before the market opens on Wednesday, February 28, 2024 via press release, which will be availabl...

2024-01-29 15:13:38 ET More on Karuna Therapeutics Karuna Therapeutics: Rewiring The Schizophrenia Paradigm - A Novel Leap Beyond Dopamine Karuna Therapeutics, Inc. (KRTX) Q3 2023 Earnings Conference Call Transcript M&A activity expected to pick up in 2024, banke...

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in a fireside chat at the B. Riley Securities Virtual Oncology Conference on Thursday, J...

2023-12-26 22:26:33 ET Summary Geron's Imetelstat shows promise for LR-MDS, especially for patients unresponsive to first-line treatments like ESAs, lenalidomide, or HMAs. Geron's financials are strong with a healthy current ratio and sufficient cash runway, but future funding nee...